Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment
Lists
Only you see this
Abstract
The discovery of novel tetrahydropyrrolo[1,2-<i>c</i>]pyrimidines derivatives from <b>Bay41_4109</b> as hepatitis B virus (HBV) inhibitors is herein reported. The structure-activity relationship optimization led to one highly efficacious compound <b>28a</b> (IC<sub>50</sub> = 10 nM) with good PK profiles and the favorite L/P ratio. The hydrodynamic injection model in mice clearly demonstrated the efficacy of <b>28a</b> against HBV replication.
BibTeX
@inproceedings{li2017design,
author = {Xiaolin Li and Kai Zhou and Haiying He and Qiong Zhou and Ya Ping Sun and Lijuan Hou and Liang Shen and Xiaofei Wang and Yuedong Zhou and Zhen Gong and Shibo He and Huangtao Jin and Zhengxian Gu and Shuyong Zhao and Long Zhang and Chunyan Sun and Shansong Zheng and Zhe Cheng and Yidong Zhu and Minghui Zhang and Jian Li and Shuhui Chen},
title = {{Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-<i>c</i>]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment}},
booktitle = {ACS},
year = {2017},
doi = {10.1021/acsmedchemlett.7b00288},
}Loading related content...